This project will establish a National biobank consortium of Taiwan through the fund support from the government. The National Health Research Institutes will establish a Central Office for the collaboration works, which includes collecting the number of samples of the human biological database in each biobank that agreed to join the Consortium. All Alliance need to follow the same SOP for the collection processthe quality of the biosample. Adequateconsistent clinical data will also be established under the Information Security Management Treaty. Since the contents of the biobanks from different institute are quite different, we will be able to quickly establish a largecomprehensive biobank network.In line with the need of biotechnologypharmaceutical industries.

Monitoring PCDM-specific biomarkers, galectin-3S100A9, to serve as a risk assessment of pancreatic cancer on new-onset diabetes patients for early detection of PC.

We constructed a model to differentiate different neurodegenerative diseases by using blood-based biomarkers. Linear Discriminant Analysis (LDA) was used to reduce dimensionsMICE (Multivariate Imputation by Chained Equations) was used for missing value treatmentchoose CART model to predict missing value imputation. This machine learning model would be used for early dectection of neurodegenerative diseases.

The key technology of Patient Derived Tumor Spheroids (PDTS) is to create an in-vitro patient tumor microenvironmenttumor-like properties, furthermore, predict various cancer antidrug effectiveness to each patient via the high-throughputhigh-quality cell viability detectionbiomarker analysis. Therefore, this project established several technologies including extracellular matrix fabrication, bioink design, cell population identification,tumor physiological environment for the upon goal.

In the current of study, cell subsets, cell proportionsthe immune function of tumors-infiltrating leukocytes were used to indicate the features of tumor immune microenvironment in non-small cell lung cancers (NSCLCs) with different type of EGFR genetic alteration.

The present technology provides a method for diagnosing Alzheimer＇s disease, including the following steps: detecting a blood sample taken from a human subject suspected of having Alzheimer＇s disease,the biomarker level is selected from G72 protein level, SLC7A11 mRNA expression level,a combination of the two,compared with a preset standard, wherein if the detected biomarker level in the blood sample is higher than the preset standard, the Individual humans are thought to have Alzheimer＇s disease.